CONVENTIONAL AND CONTROLLED-RELEASE DILTIAZEM - BIOAVAILABILITY IN HEALTHY-VOLUNTEERS AND ANTIANGINAL EFFECTS IN COMBINATION WITH METOPROLOL IN STABLE ANGINA-PECTORIS

Diltiazem CR tablets 120 mg b. i. d. for 1 week were compared with plain tablets 60 mg q. i. d. in 13 healthy male volunteers in a study of pharmacokinetic variables. Their antianginal efficacy was also compared in 23 patients with stable angina pectoris who were already on metoprolol. Both studies were of randomised, cross over design, and the clinical study was double blind. The pharmacokinetic variables of the two formulations were very similar except for the longer t(max) of 4.4 h for diltiazem CR in comparison to 2.9 h for the plain tablets. The mean relative bioavailability of diltiazem CR in comparison with plain tablets was 1.14. The clinical study showed that after four weeks on diltiazem CR 120 mg b. i. d. or diltiazem plain tablets 60 mg q. i. d. in addition to metoprolol, there were significant decreases in weekly anginal attacks from 11 to 5 attacks/week, the number of nitroglycerin tablets consumed from 6 to 3 tablets/week, and an increase in the maximum workload from 116 to 126 and 123 W for diltiazem CR and plain diltiazem tablets, respectively, as compared to placebo. Five of the patients were angina free during diltiazem treatment. No difference in anti-anginal efficacy between the two preparations was seen. It was concluded that CR 120 mg b. i. d. appears bioequivalent to plain diltiazem tablets 60 mg q. i. d.